Comparative Pharmacology
Head-to-head clinical analysis: AXID AR versus PEPCID AC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXID AR versus PEPCID AC.
AXID AR vs PEPCID AC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nizatidine is a competitive, reversible inhibitor of histamine at the H2-receptors of the gastric parietal cells, reducing gastric acid secretion.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
75 mg orally once daily at bedtime for heartburn relief; maximum 150 mg per 24 hours.
20 mg orally twice daily for 12 weeks for erosive esophagitis; 20 mg orally once daily for 4-8 weeks for GERD; 10 mg orally once daily for OTC use for heartburn.
None Documented
None Documented
Terminal elimination half-life is 1.5–2.5 hours (mean ~2 hours) in patients with normal renal function. In elderly or those with creatinine clearance <50 mL/min, half-life may extend to 4–6 hours, necessitating dose adjustment.
2.5-3.5 hours (prolonged in renal impairment, e.g., CrCl <30 mL/min: up to 20 hours)
Primarily renal; ~60% of an oral dose is excreted unchanged in urine via tubular secretion and glomerular filtration. Hepatic metabolism accounts for ~30% (N-oxidation, S-oxidation, and N-demethylation), with metabolites and small amounts of parent drug eliminated in feces via bile.
Renal (65-70% as unchanged drug), hepatic metabolism (minor), biliary/fecal (approx. 30%)
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist